Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy

被引:60
作者
Barakat, RR
Gilewski, TA
Almadrones, L
Saigo, PE
Venkatraman, E
Hudis, C
Hoskins, WJ
机构
[1] Mem Sloan Kettering Canc Ctr, Gynecol Serv, Acad Off, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Serv, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA
关键词
D O I
10.1200/JCO.2000.18.20.3459
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the frequency of developing abnormal pathologic changes in the endometria of tamoxifen-treated women. to characterize the type of pathologic changes involved. Patients and Methods: Between October 1991 and September 1998, 159 patients initiating tamoxifen therapy for breast cancer confined to the breast and axillary lymph nodes were entered in a prospective study, In this study, office endometrial biopsies (EMBs) were obtained during the initiation of tamaxifen and at 6-month intervals for a a-year period. Three subsequent annual EMBs were recorded for each patient, amounting to a 5-year surveillance. Results: One hundred fifty-nine patients with a median age of 50 years were entered onto study. Patients were assessable if EMBs were performed at least 1 year after the initiation of tamaxifen treatment. Nine patients (5.7%) were considered protocol violations. The remaining 111 assessable patients underwent a total of 635 EMBs (mean, 5.8 EMBs), with a median surveillance time of 36 months. Eighty-two (12.9%) of the 635 biopsies revealed tissue insufficient for diagnosis. Fourteen patients (12.6%) underwent dilation and curettage (D&C) for an abnormal EMB, persistent bleeding, or for evaluation of adnexal masses at the time of laparoscopy. Findings at D&C included complex hyperplasia (n = 1), abnormal histiocytes (n = 1), simple hyperplasia (n = 2), polyps (n = 4), endocervical polyp (n = 1), and decidualization (n = 2). Three D&Cs were negative. Three patients have undergone hysterectomy. Conclusion: EMB was used ta monitor the endometrium in the majority (95%) of breast cancer patients on tamaxifen in this trial, but the utility of routine EMB for screening in tamoxifen-treated women seems limited. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:3459 / 3463
页数:5
相关论文
共 29 条
  • [1] ABE O, 1992, LANCET, V339, P71
  • [2] GYNECOLOGIC EFFECTS OF TAMOXIFEN AND THE ASSOCIATION WITH ENDOMETRIAL CARCINOMA
    ASSIKIS, VJ
    JORDAN, VC
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1995, 49 (03) : 241 - 257
  • [3] 4 CASE-REPORTS PRESENTING NEW ACQUISITIONS ON THE ASSOCIATION BETWEEN BREAST AND ENDOMETRIAL CARCINOMA
    ATLANTE, G
    POZZI, M
    VINCENZONI, C
    VOCATURO, G
    [J]. GYNECOLOGIC ONCOLOGY, 1990, 37 (03) : 378 - 380
  • [4] Barakat R R, 1995, Oncology (Williston Park), V9, P129
  • [5] Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer
    Barakat, RR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 1967 - 1968
  • [6] TAMOXIFEN USE IN BREAST-CANCER PATIENTS WHO SUBSEQUENTLY DEVELOP CORPUS CANCER IS NOT ASSOCIATED WITH A HIGHER INCIDENCE OF ADVERSE HISTOLOGIC FEATURES
    BARAKAT, RR
    WONG, G
    CURTIN, JP
    VLAMIS, V
    HOSKINS, WJ
    [J]. GYNECOLOGIC ONCOLOGY, 1994, 55 (02) : 164 - 168
  • [7] Tamoxifen therapy for breast cancer and endometrial cancer risk
    Bernstein, L
    Deapen, D
    Cerhan, JR
    Schwartz, SM
    Liff, J
    McGann-Maloney, E
    Perlman, JA
    Ford, L
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) : 1654 - 1662
  • [8] *EARL BREAST CANC, 1992, LANCET, V339, P1
  • [9] Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Fisher, B
    Costantino, JP
    Wickerham, DL
    Redmond, CK
    Kavanah, M
    Cronin, WM
    Vogel, V
    Robidoux, A
    Dimitrov, N
    Atkins, J
    Daly, M
    Wieand, S
    Tan-Chiu, E
    Ford, L
    Wolmark, N
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) : 1371 - 1388
  • [10] ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14
    FISHER, B
    COSTANTINO, JP
    REDMOND, CK
    FISHER, ER
    WICKERHAM, DL
    CRONIN, WM
    BOWMAN, D
    COUTURE, J
    DIMITROV, NV
    EVANS, J
    FARRAR, W
    KAVANAH, M
    LICKLEY, HL
    MARGOLESE, R
    PATERSON, AHG
    ROBIDOUX, A
    SHIBATA, H
    TERZ, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07): : 527 - 537